CDC: Urge PrEP meds for HIV risk groups

Targeted groups include people with an infected partner and those who don't practice safe sex

CDC: Urge PrEP meds for high-risk HIV patients
CDC: Urge PrEP meds for high-risk HIV patients

HealthDay News – Patients at high risk for contracting HIV should take anti-HIV medications to cut transmission risk, according to new guidelines from the CDC.

Pre-exposure prophylaxis (PrEP) has been shown to reduce HIV infection rates in prior studies by as much as 90%, when used consistently. PrEP should be considered for the following high-risk individuals:

  • Patients who have an ongoing sexual relationship with an HIV-infected partner
  • Patients who have sex without a condom or has been diagnosed with a sexually transmitted infection within the past six months, and are not in a mutually monogamous relationship with a partner who recently tested HIV-negative
  • Patients who do not always use condoms when having sex with partners known to be at risk for HIV (for example, injecting drug users or bisexual male partners of unknown HIV status), and is not in a mutually-monogamous relationship with a partner who recently tested HIV-negative
  • Patients who have, within the past six months, injected illicit drugs and shared equipment or been in a treatment program for injection drug use

"HIV infection is preventable, yet every year we see some 50,000 new HIV infections in the United States," said CDC director Tom Frieden, MD, in a news release. "PrEP, used along with other prevention strategies, has the potential to help at-risk individuals protect themselves and reduce new HIV infections in the United States."

References

  1. United States Center for Disease Control and Prevention. (May 2014). Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014 Clinical Practice Guideline. Retrieved from: http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf
Loading links....
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Web Exclusives

Sign Up for Free e-newsletters